ABSTRACT
Receptor-mediated internalization followed by trafficking and degradation of antibody-conjugates (ACs) via the endosomal-lysosomal pathway is the major mechanism for delivering molecular payloads inside target tumor cells. Although a mainstay for delivering payloads with clinically approved ACs in cancer treatment and imaging, tumor cells are often able to decrease intracellular payload concentrations and thereby reduce the effectiveness of the desired application. Thus, increasing payload intracellular accumulation has become a focus of attention for designing next-generation ACs. We developed a composite compound (ChAcNLS) that enables ACs to escape endosome entrapment and route to the nucleus resulting in the increased intracellular accumulation as an interleukin-5 receptor α-subunit (IL-5Rα)-targeted agent for muscle invasive bladder cancer (MIBC). We constructed 64Cu-A14-ChAcNLS, 64Cu-A14-NLS, and 64Cu-A14 and evaluated their performance by employing mechanistic studies for endosome escape coupled to nuclear routing and determining whether this delivery system results in improved 64Cu cellular accumulation. ACs consisting of â¼20 ChAcNLS or NLS moieties per 64Cu-A14 were prepared in good yield, high monomer content, and maintaining high affinity for IL-5Rα. Confocal microscopy analysis demonstrated ChAcNLS mediated efficient endosome escape and nuclear localization. 64Cu-A14-ChAcNLS increased 64Cu cellular accumulation in HT-1376 and HT-B9 cells relative to 64Cu-A14 and 64Cu-A14-NLS. In addition, we tested 64Cu-A14-ChAcNLS in vivo to evaluate its tissue distribution properties and, ultimately, tumor uptake and targeting. A model of human IL-5Rα MIBC was developed by implanting NOD/SCID mice with subcutaneous HT-1376 or HT-B9MIBC tumors, which grow containing high and low IL-5Rα-positive tumor cell densities, respectively. ACs were intravenously injected, and daily blood sampling, biodistribution at 48 and 96 h, and positron emission tomography (PET) at 24 and 48 h were performed. Region of interest (ROI) analysis was also performed on reconstructed PET images. Pharmacokinetic analysis and biodistribution studies showed that 64Cu-A14-ChAcNLS had faster clearance rates from the blood and healthy organs relative to 64Cu-A14. However, 64Cu-A14-ChAcNLS maintained comparable tumor accumulation relative to 64Cu-A14. This resulted in 64Cu-A14-ChAcNLS having superior tumor/normal tissue ratios at both 48 and 96 h biodistribution time points. Visualization of AC distribution by PET and ROI analysis confirmed that 64Cu-A14-ChAcNLS had improved targeting of MIBC tumor relative to 64Cu-A14. In addition, 64Cu-A14 modified with only NLS had poor tumor targeting. This was a result of poor tumor uptake due to extremely rapid clearance. Thus, the overall findings in this model of human IL-5Rα-positive MIBC describe an endosome escape-nuclear localization cholic-acid-linked peptide that substantially enhances AC cellular accumulation and tumor targeting.
Subject(s)
Cholic Acid/chemistry , Cholic Acid/pharmacokinetics , Immunoconjugates/chemistry , Immunoconjugates/pharmacokinetics , Interleukin-5 Receptor alpha Subunit/analysis , Urinary Bladder Neoplasms/diagnostic imaging , Animals , Cell Line, Tumor , Cholic Acid/administration & dosage , Copper Radioisotopes/administration & dosage , Copper Radioisotopes/chemistry , Copper Radioisotopes/pharmacokinetics , Drug Delivery Systems , Humans , Immunoconjugates/administration & dosage , Immunoconjugates/immunology , Interleukin-5 Receptor alpha Subunit/immunology , Mice, Inbred NOD , Mice, SCID , Positron-Emission Tomography/methods , Tissue Distribution , Urinary Bladder Neoplasms/immunology , Urinary Bladder Neoplasms/therapyABSTRACT
The evaluation of individual variability in endogenous drugs' metabolism and disposition is a very challenging task. We developed and validated a metabotype to pharmacokinetics (PK) matching approach by taking cholic acid as an example to predict the individualized PK of endogenous drugs. The stable isotope-labeled cholic acid was selected as the substitute analyte of cholic acid to ensure the accurate measurement of blood concentration. First, large-scale metabolite profiling studies were performed on the predose urine samples of 28 rats. Then, to examine the individualized PK of deuterium 4-cholic acid (d4-cholic acid) in these rats, we determined its plasma concentrations and calculated the differential AUC values. Subsequently, we conducted a two-stage partial least-squares analysis in which 31 baseline metabolites were screened initially for predicting the individualized AUC values of d4-cholic acid using the data of predose urine metabolites. Finally, network biology analysis was applied to give the biological interpretation of the individual variances in cholic acid metabolism and disposition, and the result further narrowed the selection of baseline metabolites from 31 to 2 (sarcosine and S-adenosyl-l-homocysteine) for such prediction. Collectively, this pharmacometabolomics research provided a new strategy for predicting individualized PK of endogenous drugs.
Subject(s)
Cholic Acid/pharmacokinetics , Metabolome/genetics , Metabolomics , Animals , Area Under Curve , Cholic Acid/blood , Cholic Acid/urine , Humans , Isotope Labeling , RatsABSTRACT
The design of antibody-conjugates (ACs) for delivering molecules for targeted applications in humans has sufficiently progressed to demonstrate clinical efficacy in certain malignancies and reduced systemic toxicity that occurs with standard nontargeted therapies. One area that can advance clinical success for ACs will be to increase their intracellular accumulation. However, entrapment and degradation in the endosomal-lysosomal pathway, on which ACs are reliant for the depositing of their molecular payload inside target cells, leads to reduced intracellular accumulation. Innovative approaches that can manipulate this pathway may provide a strategy for increasing accumulation. We hypothesized that escape from entrapment inside the endosomal-lysosomal pathway and redirected trafficking to the nucleus could be an effective approach to increase intracellular AC accumulation in target cells. Cholic acid (ChAc) was coupled to the peptide CGYGPKKKRKVGG containing the nuclear localization sequence (NLS) from SV-40 large T-antigen, which is termed ChAcNLS. ChAcNLS was conjugated to the mAb 7G3 (7G3-ChAcNLS), which has nanomolar affinity for the cell-surface leukemic antigen interleukin-3 receptor-α (IL-3Rα). Our aim was to determine whether 7G3-ChAcNLS increased intracellular accumulation while retaining nanomolar affinity and IL-3Rα-positive cell selectivity. Competition ELISA and cell treatment assays were performed. Cell fractionation, confocal microscopy, flow cytometry, and Western blot techniques were used to determine the level of antibody accumulation inside cells and in corresponding nuclei. In addition, the radioisotope copper-64 ((64)Cu) was also utilized as a surrogate molecular cargo to evaluate nuclear and intracellular accumulation by radioactivity counting. 7G3-ChAcNLS effectively escaped endosome entrapment and degradation resulting in a unique intracellular distribution pattern. mAb modification with ChAcNLS maintained 7G3 nM affinity and produced high selectivity for IL-3Rα-positive cells. In contrast, 7G3 ACs with the ability to either escape endosome entrapment or traffic to the nucleus was not superior to 7G3-ChAcNLS for increasing intracellular accumulation. Transportation of (64)Cu when complexed to 7G3-ChAcNLS also resulted in increased nuclear and intracellular radioactivity accumulation. Thus, ChAcNLS is a novel mAb functionalizing technology that demonstrates its ability to increase AC intracellular accumulation in target cells through escaping endosome entrapment coupled to nuclear trafficking.
Subject(s)
Antibodies, Monoclonal/pharmacology , Cell Nucleus/drug effects , Cholic Acid/pharmacokinetics , Endosomes/drug effects , Immunoconjugates/pharmacology , Cell Line, Tumor , Cell Nucleus/metabolism , Cell Survival/drug effects , Endosomes/metabolism , Humans , Interleukin-3 Receptor alpha Subunit/metabolism , Lysosomes/drug effects , Lysosomes/metabolism , Nuclear Localization Signals/metabolism , Peptides/metabolismABSTRACT
BACKGROUND: The high incidence of cholesterol gallstones in patients after proctocolectomy with ileal pouch-anal anastomosis (IPAA) may be due to an increased loss of bile acids. We aimed to evaluate the kinetics of the primary bile acids cholic acid (CA) and chenodeoxycholic acid (CDCA) in these patients. METHODS: Pool sizes, synthesis rates, and fractional turnover rates of CA and CDCA were determined by combined capillary gas chromatography/isotope ratio mass spectrometry in serum samples after administration of [¹³C]CA and [¹³C]CDCA in 6 patients and 9 healthy volunteers. RESULTS: In patients with IPAA, pool sizes of CA and CDCA were 11.5 (8.2-23.8) and 12.1 (6.7-20.1) µmol/kg, respectively, and were significantly lower than in healthy controls [36.0 (24-47) and 29.0 (21-42) µmol/kg, respectively; p < 0.05, each]. Fractional turnover rates of CA [1.19 (1.06-1.82) vs. 0.31 (0.13-0.54) per day] and CDCA [1.01 (0.50-1.63) vs. 0.23 (0.09-0.36) per day] were increased fourfold in patients with IPAA (p < 0.05, each). Synthesis rates of CDCA [10.2 (5.2-32.9) vs. 6.6 (2.7-10.5) µmol/kg per day, p = 0.05] and CA [15.1 (9.3-39.4) vs. 11.5 (3.1-20.5) µmol/kg per day, n.s.] tended to be higher in patients with IPAA than in controls. CONCLUSION: The reduced pool size of primary bile acids may contribute to the high incidence of cholesterol gallstones in patients after proctocolectomy and IPAA.
Subject(s)
Anal Canal/surgery , Chenodeoxycholic Acid/pharmacokinetics , Cholic Acid/pharmacokinetics , Colonic Pouches , Proctocolectomy, Restorative , Adult , Anastomosis, Surgical , Case-Control Studies , Female , Humans , Male , Middle AgedABSTRACT
Lipid-polysaccharide modified biohybrid nanoparticles (NPs) are eminent drug carriers for brain targeting, owing to their ability to prolong the circulation time and penetrate the blood brain barrier (BBB). Biohybrid NPs particular interest arises from their potential to mimic biological components. Herein, we prepared bioinspired lipid polymeric NPs, either naked or surface modified by a synthesized biocompatible dextran-cholic acid (DxC). The nanoprecipitation method was tailored to allow the assembly of the multicomponent NPs in a single step. Modulating the solvent/antisolvent system provided lipid polymer hybrid NPs in the size of 111.6 ± 11.4 nm size. The NPs encapsulated up to 92 ± 1.2% of a hydrophilic anti-Alzheimer drug, rivastigmine (Riv). The brain uptake, biodistribution and pharmacokinetics studies, proved the efficient fast penetration of the bioinspired surface modified NPs to the brain of healthy albino rats. The modified nanocarrier caused a 5.4 fold increase in brain targeting efficiency compared to the drug solution. Furthermore, the presence of DxC increased Riv's brain residence time up to 40 h. The achieved results suggest that the fabricated biohybrid delivery system was able to circumvent the BBB and is expected to minimize Riv systemic side effects.
Subject(s)
Blood-Brain Barrier/metabolism , Lipids , Nanoparticles , Polysaccharides , Rivastigmine , Animals , Cholic Acid/chemistry , Cholic Acid/pharmacokinetics , Cholic Acid/pharmacology , Dextrans/chemistry , Dextrans/pharmacokinetics , Dextrans/pharmacology , Drug Carriers/chemistry , Drug Carriers/pharmacokinetics , Drug Carriers/pharmacology , Hydrophobic and Hydrophilic Interactions , Lipids/chemistry , Lipids/pharmacokinetics , Lipids/pharmacology , Male , Nanoparticles/chemistry , Nanoparticles/therapeutic use , Polysaccharides/chemistry , Polysaccharides/pharmacokinetics , Polysaccharides/pharmacology , Rats , Rivastigmine/chemistry , Rivastigmine/pharmacokinetics , Rivastigmine/pharmacologyABSTRACT
Molecular umbrella provided a promising avenue for the design of the intracellular delivery of hydrophilic therapeutic agents. However, the limited understanding of its cellular uptake would be a roadblock to its effective application. Herein, we investigate the ability and mechanism of cellular entry of a fluorescently labeled diwalled molecular umbrella, which was synthesized from cholic acid, spermine, and 5-carboxyfluorescein, into Hela cells, with the extent of uptake analyzed by confocal fluorescence microscopy and flow cytometry. It is found that the as-synthesized diwalled molecular umbrella can greatly facilitate cellular uptake of hydrophilic agent, 5-carboxyfluorescein. In vitro experiments with diffuse marker, endocytic marker, and inhibitors suggested that several distinct uptake pathways (e.g., passive diffuse, clathrin-mediated endocytosis, and caveolae/lipid-raft-dependent endocytosis) are involved in the internalization of diwalled molecular umbrella. These results, together with its low toxicity and good biocompatibility, thus demonstrate the suitability of molecular umbrella for application as vectors in drug delivery systems.
Subject(s)
Biocompatible Materials/metabolism , Cell Membrane/metabolism , Cholic Acid/metabolism , Drug Carriers/metabolism , Fluorescent Dyes/metabolism , Spermidine/metabolism , Biocompatible Materials/chemistry , Biocompatible Materials/pharmacokinetics , Biological Transport , Cell Membrane/chemistry , Cells, Cultured , Cholic Acid/chemistry , Cholic Acid/pharmacokinetics , Drug Carriers/chemistry , Drug Carriers/pharmacokinetics , Drug Delivery Systems , Fluoresceins/chemistry , Fluoresceins/metabolism , Fluorescent Dyes/chemistry , Fluorescent Dyes/pharmacokinetics , HeLa Cells , Humans , Hydrophobic and Hydrophilic Interactions , Lipid Bilayers/chemistry , Lipid Bilayers/metabolism , Molecular Conformation , Spermidine/chemistry , Spermidine/pharmacokinetics , Structure-Activity RelationshipABSTRACT
The objective of this work was to develop a liver-specific antihepato carcinoma agent. A series of 5-fluorouracil / cholic acid conjugates (5-FU-cholic acid conjugates) were prepared and tested for their chemical characteristics and bio-distribution properties. The in-vitro stability trial showed 5-FU-cholic acid conjugates could be completely hydrolyzed by heating at 70 degrees C in an acidic solution, pH = 1, for 5 min. The fast and complete hydrolysis of these compounds could be compatible with a fast separation and analysis method to shorten the analysis time. The decomposition speeds of the 5-FU-cholic acid conjugates in different organs of mice at several time points after oral administration were evaluated by measuring the concentrations of regenerated 5-FU in organ tissue. The results were compared with those of the controls, which was a group of mice orally taking 5-FU. The concentrations of 5-FU in mice liver tissue were remarkably increased after oral administration of the prodrugs, and were much larger than if only orally administered 5-FU. The results suggested the feasibility to improve therapeutic efficiency of liver targeting treatments by using cholic acid as the vector of drugs.
Subject(s)
Antineoplastic Agents/chemical synthesis , Drug Delivery Systems/methods , Liver/drug effects , Prodrugs , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacokinetics , Cholic Acid/chemistry , Cholic Acid/pharmacokinetics , Female , Fluorouracil/chemistry , Fluorouracil/pharmacokinetics , Mice , Molecular Structure , Prodrugs/chemical synthesis , Prodrugs/chemistry , Prodrugs/pharmacokinetics , Tissue DistributionABSTRACT
The search for new drugs for the treatment of leishmaniasis is an important strategy for improving the current therapeutic arsenal for the disease. There are several limitations to the available drugs including high toxicity, low efficacy, prolonged parenteral administration, and high costs. Steroids are a diverse group of compounds with various applications in pharmacology. However, the antileishmanial activity of this class of molecules has not yet been explored. Therefore, in the present study, we investigated the antileishmanial activity and cytotoxicity of novel steroids against murine macrophages with a focus on the derivatives of cholesterol (CD), cholic acid (CA), and deoxycholic acid (DA). Furthermore, the mechanism of action of the best compound was assessed, and in silico studies to evaluate the physicochemical and pharmacokinetic properties were also conducted. Among the sixteen derivatives, schiffbase2, CD2 and deoxycholic acid derivatives (DOCADs) were effective against promastigotes of Leishmania species. Despite their low toxicity to macrophages, the majority of DOCADs were active against intracellular amastigotes of L. amazonensis, and DOCAD5 exhibited the best biological effect against these parasitic stages (IC50 = 15.34 µM). Neither the CA derivatives (CAD) nor DA alone inhibited the intracellular parasites. Thus, the absence of hydroxyl in the C-7 position of the steroid nucleus, as well as the modification of the acid group in DOCADs were considered important for antileishmanial activity. The treatment of L. amazonensis promastigote forms with DOCAD5 induced biochemical changes such as depolarization of the mitochondrial membrane potential, increased ROS production and cell cycle arrest. No alterations in parasite plasma membrane integrity were observed. In silico physicochemical and pharmacokinetic studies suggest that DOCAD5 could be a good candidate for an oral drug. The data demonstrate the potential antileishmanial effect of certain steroid derivatives and encourage new in vivo studies.
Subject(s)
Cholesterol/pharmacology , Deoxycholic Acid/pharmacology , Drug Discovery/methods , Leishmania/drug effects , Leishmaniasis/drug therapy , Macrophages, Peritoneal/drug effects , Trypanocidal Agents/pharmacology , Administration, Oral , Animals , Cell Cycle Checkpoints/drug effects , Cholesterol/analogs & derivatives , Cholesterol/chemical synthesis , Cholesterol/pharmacokinetics , Cholic Acid/chemical synthesis , Cholic Acid/pharmacokinetics , Cholic Acid/pharmacology , Deoxycholic Acid/analogs & derivatives , Deoxycholic Acid/chemical synthesis , Deoxycholic Acid/pharmacokinetics , Dose-Response Relationship, Drug , Leishmania/growth & development , Leishmania/metabolism , Leishmaniasis/parasitology , Macrophages, Peritoneal/parasitology , Membrane Potential, Mitochondrial/drug effects , Mice, Inbred BALB C , Mitochondria/drug effects , Mitochondria/metabolism , Models, Biological , Molecular Structure , Oxidative Stress/drug effects , Parasitic Sensitivity Tests , Structure-Activity Relationship , Trypanocidal Agents/chemical synthesis , Trypanocidal Agents/pharmacokineticsABSTRACT
A simple, rapid, and specific analytical method for simultaneous determination of geniposide, baicalin, cholic acid and hyodeoxycholic acid in 50 microL samples of rat serum was developed by high performance liquid chromatography-tandem mass spectrometry. The quantification of the target compounds was determined by multiple reaction monitoring (MRM) mode using electrospray ionization (ESI). The correlation coefficients of the calibration curves were better than 0.997. The intra- and inter-day accuracy, precision, and linear range had been investigated in detail. This method was subsequently applied to pharmacokinetic studies of geniposide, baicalin, cholic acid and hyodeoxycholic acid in rats successfully.
Subject(s)
Cholic Acid/blood , Chromatography, High Pressure Liquid/methods , Deoxycholic Acid/blood , Flavonoids/blood , Iridoids/blood , Pyrans/blood , Spectrometry, Mass, Electrospray Ionization/methods , Animals , Calibration , Cholic Acid/pharmacokinetics , Deoxycholic Acid/pharmacokinetics , Flavonoids/pharmacokinetics , Iridoids/pharmacokinetics , Male , Pyrans/pharmacokinetics , Rats , Rats, Wistar , Reference StandardsABSTRACT
Cholic acid (CA) was coupled with amine-terminated poly (N-isopropylacrylamide) (ATPNIPAAm) using N,N'-dicyclohexyl carbodiimide as a coupling agent. Self-assembled CA/PNIPAAm conjugate (abbreviated as CN) micelles were prepared by diafiltration method in water. The CN micelles exhibited the lower critical solution temperature (LCST) at 31.5 degrees C. The CN micelles were observed as spherical shapes and their dried sizes were ranged between 30 and 50 nm by the transmission electron microscope (TEM) images. Hydrated micelle sizes measured by photon correlation spectroscopy (PCS) were ranged 337.5+/-67.8 nm. And reversible size changes of CN micelles were observed with two point temperature 10 and 40 degrees C, respectively. From the fluorescence spectra, fluorescence intensity of pyrene in the CN micelles was increased and red-shifted as the concentration of CN increased, indicating the formation of self-assembled polymeric micelles in water. The critical micelle concentration (CMC) was evaluated as 8.9 x 10(-2) g/l. Much more indomethacin (IN) was released from th CN micelles at 10 than at 40 degrees C due to the thermo-sensitivity of the PNIPAAm in the CN polymer.
Subject(s)
Drug Delivery Systems , Micelles , Polymers/pharmacokinetics , Temperature , Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics , Cholic Acid/chemistry , Cholic Acid/pharmacokinetics , Indomethacin/pharmacokinetics , Particle Size , Polymers/chemistryABSTRACT
Different backbone modified antisense oligonucleotides (AS-ODNs) directed against the hepatitis C virus genome were 5'-conjugated to cholesterol, cholic acid or taurocholic acid to enhance liver specific drug targeting and hepatocellular uptake. The lipophilic character of modified AS-ODNs was determined from RP-HPLC retention times and duplex stability was correlated with Tm-values from UV melting curves.
Subject(s)
Hepacivirus/genetics , Liver/metabolism , Oligonucleotides, Antisense/chemistry , Oligonucleotides, Antisense/genetics , Cholesterol/analogs & derivatives , Cholesterol/chemistry , Cholesterol/pharmacokinetics , Cholic Acid/chemistry , Cholic Acid/pharmacokinetics , Chromatography, High Pressure Liquid , Drug Design , Hepacivirus/drug effects , Oligonucleotides, Antisense/pharmacokinetics , Organ Specificity , Taurocholic Acid/analogs & derivatives , Taurocholic Acid/chemistry , Taurocholic Acid/pharmacokineticsABSTRACT
Previously, we developed a trifluorinated bile acid, CA-lys-TFA, with the objective of noninvasively assessing bile acid transport in vivo using (19) F magnetic resonance imaging (MRI). CA-lys-TFA was successfully imaged in the mouse gallbladder, but was susceptible to deconjugation in vitro by choloylglycine hydrolase (CGH), a bacterial bile acid deconjugating enzyme found in the terminal ileum and colon. The objective of the present study was to develop a novel trifluorinated bile acid resistant to deconjugation by CGH. CA-sar-TFMA was designed, synthesized, and tested for in vitro transport properties, stability, imaging properties, and its ability to differentially accumulate in the gallbladders of normal mice, compared with mice with known impaired bile acid transport (deficient in the apical sodium-dependent bile acid transporter, ASBT). CA-sar-TFMA was a potent inhibitor and substrate of ASBT and the Na(+) /taurocholate cotransporting polypeptide. Stability was favorable in all conditions tested, including the presence of CGH. CA-sar-TFMA was successfully imaged and accumulated at 16.1-fold higher concentrations in gallbladders from wild-type mice compared with those from Asbt-deficient mice. Our results support the potential of using MRI with CA-sar-TFMA as a noninvasive method to assess bile acid transport in vivo.
Subject(s)
Cholic Acid , Contrast Media , Fluorine-19 Magnetic Resonance Imaging , Gallbladder/metabolism , Intestinal Mucosa/metabolism , Lysine/analogs & derivatives , Administration, Oral , Animals , Biological Transport , Cholic Acid/administration & dosage , Cholic Acid/pharmacokinetics , Contrast Media/administration & dosage , Contrast Media/pharmacokinetics , Dogs , Fluorine-19 Magnetic Resonance Imaging/instrumentation , HEK293 Cells , Humans , Lysine/administration & dosage , Lysine/pharmacokinetics , Madin Darby Canine Kidney Cells , Male , Mice, Inbred C57BL , Mice, Knockout , Organic Anion Transporters, Sodium-Dependent/deficiency , Organic Anion Transporters, Sodium-Dependent/genetics , Phantoms, Imaging , Pilot Projects , Symporters/deficiency , Symporters/genetics , Tissue Distribution , TransfectionABSTRACT
Cholesterol (CH) homeostasis in the liver is regulated by enzymes of CH synthesis such as 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) and catabolic enzymes such as cytochrome P-450, family 7, subfamily A, and polypeptide 1 (CYP7A1). Since a circadian clock controls the gene expression of these enzymes, these genes exhibit circadian rhythm in the liver. In this study, we examined the relationship between a diet containing CH and/or cholic acid (CA) and the circadian regulation of Hmgcr, low-density lipoprotein receptor (Ldlr), and Cyp7a1 gene expression in the mouse liver. A 4-wk CA diet lowered and eventually abolished the circadian expression of these genes. Not only clock genes such as period homolog 2 (Drosophila) (Per2) and brain and muscle arnt-like protein-1 (Bmal1) but also clock-controlled genes such as Hmgcr, Ldlr, and Cyp7a1 showed a reduced and arrhythmic expression pattern in the liver of Clock mutant mice. The reduced gene expression of Cyp7a1 in mice fed a diet containing CA or CH + CA was remarkable in the liver of Clock mutants compared with wild-type mice, and high liver CH accumulation was apparent in Clock mutant mice. In contrast, a CH diet without CA only elevated Cyp7a1 expression in both wild-type and Clock mutant mice. The present findings indicate that normal circadian clock function is important for the regulation of CH homeostasis in the mouse liver, especially in conjunction with a diet containing high CH and CA.
Subject(s)
Cholesterol, Dietary/pharmacokinetics , Cholic Acid/pharmacokinetics , Circadian Rhythm/physiology , Liver/metabolism , Trans-Activators/genetics , ARNTL Transcription Factors , Acyl Coenzyme A/genetics , Animal Feed , Animals , Basic Helix-Loop-Helix Transcription Factors/genetics , Brain/physiology , CLOCK Proteins , Cell Cycle Proteins/genetics , Cell Cycle Proteins/metabolism , Cholesterol 7-alpha-Hydroxylase/genetics , Cholesterol 7-alpha-Hydroxylase/metabolism , Cholesterol, Dietary/blood , DNA-Binding Proteins/genetics , Gene Expression/physiology , Homeostasis/physiology , Male , Mice , Mice, Inbred ICR , Mice, Mutant Strains , Muscle, Skeletal/physiology , Mutation , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Period Circadian Proteins , Receptors, LDL/genetics , Sterol Regulatory Element Binding Protein 2/genetics , Trans-Activators/metabolism , Transcription Factors/genetics , Transcription Factors/metabolismABSTRACT
A stable isotope dilution method is described that allows measurement of cholic acid (CA) kinetics, that is, pool size, fractional turnover rate (FTR), and synthesis rate in mice, rats, and humans. Decay of administered [2,2,4,4-2H4]CA enrichment was measured in time in 50-microl plasma samples by gas-liquid chromatography/electron capture negative chemical ionization-mass spectrometry, applying the pentafluorobenzyl-trimethylsilyl derivative. The kinetic data expressed species-dependent differences. The CA pool sizes were 16.8 +/- 2.1, 10.6 +/- 1.2, and 2.4 +/- 0.7 micromol/100 g body weight for mice, rats, and humans, respectively. The FTR values were 0.44 +/- 0.03, 0.88 +/- 0.10, and 0.46 +/- 0.14 per day for mice, rats, and humans. The corresponding synthesis rates were 7.3 +/- 1.6, 9.3 +/- 0.1, and 1.0 +/- 0.2 micromol/100 g body weight per day. The human data agreed well with literature data obtained by conventional isotope dilution techniques. For rats and mice these are the first reported isotope dilution data. The method was validated by confirmation of isotopic equilibrium between biliary CA and plasma CA in the rat. Its applicability was demonstrated by the observation of increased CA FTR and CA synthesis rate in rats fed cholestyramine, which is known to increase fecal bile acid excretion. The presented stable isotope dilution method enables the determination of CA kinetic parameters in small plasma samples. The method can be applied in unanesthetized rodents with an intact enterohepatic circulation and may also be valuable when studying the development of human neonatal bile acid kinetics.
Subject(s)
Cholic Acid/blood , Cholic Acid/pharmacokinetics , Deuterium , Indicator Dilution Techniques , Adult , Animals , Bile/metabolism , Cholestyramine Resin/administration & dosage , Cholic Acid/administration & dosage , Diet , Feces/chemistry , Female , Gas Chromatography-Mass Spectrometry , Humans , Kinetics , Linear Models , Male , Mass Spectrometry , Middle Aged , Rats , Rats, Wistar , Sensitivity and SpecificityABSTRACT
BACKGROUND: Colestimide is a newly developed bile acid-binding resin in Japan, but its bile acid-binding properties have not been studied. METHODS: The absorption of unconjugated bile acids (5 mmol/L) in the ligated rat jejunum was compared in the presence and absence of colestimide. Furthermore, bile acid adsorption by colestimide was also studied in vitro. RESULTS: All bile acids were efficiently absorbed in the jejunum and the cumulative absorption during 120 min was 29-63%. The absorption of chenodeoxycholate, lithocholate, deoxycholate and ursodeoxycholate was dose-dependently inhibited by 2.5 and 5 mg colestimide, whereas the absorption of cholate was not inhibited, even in the presence of 5 mg colestimide. Adsorption of bile acids by colestimide in vitro was approximately 60% for chenodeoxycholate, lithocholate, deoxycholate and ursodeoxycholate, whereas the adsorption of cholate was low (16%). CONCLUSIONS: Jejunal absorption of ursodeoxycholate was inhibited by colestimide to a similar extent as other dihydroxy bile acids, whereas that of cholate was not inhibited under the same conditions.
Subject(s)
Anion Exchange Resins/pharmacology , Deoxycholic Acid/pharmacokinetics , Intestinal Absorption/drug effects , Jejunum/metabolism , Animals , Anion Exchange Resins/metabolism , Bile Acids and Salts/pharmacokinetics , Cholic Acid/pharmacokinetics , Epichlorohydrin , Imidazoles , Male , Rats , Rats, Sprague-Dawley , Resins, Synthetic , Time FactorsABSTRACT
BACKGROUND & AIMS: Prolonged large bowel transit, and an increase in the proportion of deoxycholic acid (DCA), have been implicated in the pathogenesis of cholesterol gallstones-including those developing in acromegalics treated with octreotide. However, there are few data on the effects of intestinal transit on bile acid kinetics. METHODS: We therefore measured the kinetics of DCA and cholic acid (CA) using stable isotopes, serum sampling, and mass spectrometry. The results were related to mouth-to-caecum (MCTT) and large bowel transit times (LBTTs) in 4 groups of 8 individuals: (1) non-acromegalic controls, (2) acromegalics untreated with octreotide, (3) acromegalics on long-term octreotide, and (4) patients with constipation. Paired, before and during octreotide, studies were performed in 5 acromegalics. RESULTS: In the unpaired and paired studies, octreotide significantly prolonged MCTT and LBTT. In the paired studies, the octreotide-induced prolongation of LBTT caused an increase in the DCA input rate (6.4 +/- 2.8 to 12 +/- 2.6 micromol. kg. d, P < 0.05) and pool size (18 +/- 12 to 40 +/- 13 micromol/kg, P < 0.05), and a decrease in CA pool size (45 +/- 15 to 25 +/- 11 micromol/kg, P < 0.05). Furthermore, during octreotide treatment, the mean conversion of 13C-CA to 13C-DCA (micromoles) was greater (P < 0.05) on study days 3, 4, and 5. There were also positive linear relationships between LBTT and DCA input rate (r = 0.78), pool size (r = 0.82, P < 0.001), and a weak (r = -0.49) negative linear relationship between LBTT and CA pool size (P < 0.01). CONCLUSIONS: These data support the hypothesis that, by increasing DCA formation and absorption, prolongation of large bowel transit is a pathogenic factor in the formation of octreotide-induced gallstones.
Subject(s)
Acromegaly/metabolism , Colon/physiology , Deoxycholic Acid/pharmacokinetics , Acromegaly/blood , Acromegaly/drug therapy , Adult , Aged , Body Weight , Carbon Isotopes , Cholic Acid/biosynthesis , Cholic Acid/blood , Cholic Acid/pharmacokinetics , Colon/physiopathology , Deoxycholic Acid/blood , Deuterium , Female , Humans , Male , Middle Aged , Octreotide/therapeutic use , Postprandial PeriodABSTRACT
Unconjugated bile acids such as cholic acid cause diarrhoea, mucosal irritation and toxicity. We sought to define the mechanism of cholate permeation across intestinal mucosal cells to understand how cellular exposure and accumulation are deleterious to mucosal function. Human intestinal Caco-2 and T84 cell monolayers were prepared by high-density seeding and cultured for >14 days on permeable culture supports. Cholate transport and cellular accumulation were determined using [3H]cholic acid. Epithelial barrier function was assessed by measuring transepithelial electrical resistance (Rt) and [14C]mannitol fluxes. Exposure of Caco-2 epithelia to serosal cholate caused a dose- and time-dependent disruption of barrier function. Apical exposure was without disruptive effect. Similar responses were observed for T84 epithelia. Cholate was preferentially accumulated across the basolateral surfaces in both Caco-2 and T84 cells, but was subject to active transepithelial secretion in Caco-2 monolayers only. Net secretion was substantially reduced by ATP depletion, showed saturation kinetics, and was subject to competitive inhibition by other bile acids. Cholate secretion was also sensitive to inhibition by the leukotriene antagonist MK-571 but not by digoxin, suggesting that MRP2, not MDR1, was responsible. RT-PCR and Western blotting confirmed MRP2 expression in Caco-2 epithelia but indicated its apparent absence from T84 cells.
Subject(s)
Cholic Acid/pharmacology , Enterocytes/drug effects , Enterocytes/metabolism , Absorption , Adenosine Triphosphate/physiology , Bile Acids and Salts/pharmacology , Biological Transport , Caco-2 Cells , Cell Line , Cholic Acid/pharmacokinetics , Electric Impedance , Enterocytes/physiology , Humans , Intestinal Mucosa/metabolism , Mannitol/pharmacokinetics , Membranes/metabolism , Permeability/drug effectsABSTRACT
The rat liver organic anion transporting polypeptide (Oatp1) has been extensively characterized mainly in the Xenopus laevis expression system as a polyspecific carrier transporting organic anions (bile salts), neutral compounds, and even organic cations. In this study, we extended this characterization using a mammalian expression system and confirm the basolateral hepatic expression of Oatp1 with a new antibody. Besides sulfobromophthalein [Michaelis-Menten constant (Km) of approximately 3 microM], taurocholate (Km of approximately 32 microM), and estradiol- 17beta-glucuronide (Km of approximately 4 microM), substrates previously shown to be transported by Oatp1 in transfected HeLa cells, we determined the kinetic parameters for cholate (Km of approximately 54 microM), glycocholate (Km of approximately 54 microM), estrone-3-sulfate (Km of approximately 11 microM), CRC-220 (Km of approximately 57 microM), ouabain (Km of approximately 3,000 microM), and ochratoxin A (Km of approximately 29 microM) in stably transfected Chinese hamster ovary (CHO) cells. In addition, three new substrates, taurochenodeoxycholate (Km of approximately 7 microM), tauroursodeoxycholate (Km of approximately 13 microM), and dehydroepiandrosterone sulfate (Km of approximately 5 microM), were also investigated. The results establish the polyspecific nature of Oatp1 in a mammalian expression system and definitely identify conjugated dihydroxy bile salts and steroid conjugates as high-affinity endogenous substrates of Oatp1.